[{"id":"3934af03-057a-40fc-b82b-923f171f3da0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00770185","created_at":"2021-01-18T02:54:34.894Z","updated_at":"2025-02-25T14:55:16.957Z","phase":"Phase 2","brief_title":"Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer","source_id_and_acronym":"NCT00770185","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Taltorvic (ridaforolimus)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 11/13/2008","start_date":" 11/13/2008","primary_txt":" Primary completion: 03/19/2012","primary_completion_date":" 03/19/2012","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"a029591e-46da-4354-9f40-6f34e9c1d8c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01234857","created_at":"2021-01-18T04:58:05.618Z","updated_at":"2024-07-02T16:37:21.547Z","phase":"Phase 2","brief_title":"A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)","source_id_and_acronym":"NCT01234857","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Taltorvic (ridaforolimus) • dalotuzumab (MK 0646)"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 09/17/2010","start_date":" 09/17/2010","primary_txt":" Primary completion: 10/15/2013","primary_completion_date":" 10/15/2013","study_txt":" Completion: 10/15/2013","study_completion_date":" 10/15/2013","last_update_posted":"2017-05-31"}]